Table 2.
Selected baseline characteristics in individual studies
| Author/Reference | Male,% | Age, years, mean (SD) | PD duration, years mean (SD) |
Trial interventions | Daily levodopa dose in mg, mean (SD) | Daily levodopa equivalent dose in mg, mean (SD) |
|---|---|---|---|---|---|---|
| Antonini et al. (2017) [25] | 59 | 66.4 (8.8) | 12.7 (6.3) | LCIG | 905.5 (443.5) | 1061.3 (555.5) |
| Fernandez et al. (2015) [23] | 59 | 64.0 (9.1) | 12.2 (5.6) | LCIG | 1080.3 (546.7) | NA |
| Palhagen et al. (2016) [24] | 62 | 63.6 (7.6) | 11 (4.4) | LCIG | NA | NA |
| De Fabregues et al. (2017) [36] | 59 | 68.2 (6.8) | 13.5 (5.6) | LCIG | NA | NA |
| Honig et al. (2009) [40] | 73 | 58.6 (9.1) | 15.3 (5.9) | LCIG | NA | NA |
| Vijiaratanam et al. (2018) [47] | 55 | 70.7 (6.9) | 15.2 (6.8) | LCIG | NA | 1655 (546) |
| Murata et al. (2016) [44] | 39 | 61.6 (10.5) | 12.4 (5.1) | LCIG | 1011.7 (629.7) | NA |
| Floden et al. (2015) [39] | 75 | 62.4 (7.9) | 10.6 (5.1) | DBS | NA | 958.5 (517.7) |
| Dafsari et al. (2016) [48] | 58 | 61.6 (7.8) | 10.5 (4.2) | DBS | NA | 1073.55 (475.93) |
| Dafsari et al. (2018) [34] | 75 | 62.3 (7.8) | 10.9 (4.8) | DBS | NA | 1121.6 (515.2) |
| Kubu et al. (2017) [41] | 75 | 61.3 (9.3) | 9.1 (4.1) | DBS | NA | NA |
| Soulas et al. (2011) [45] | NA | 62.0 (8.0) | 14.5 (5.7) | DBS | NA | 1504 (667.32) |
| Timmermann et al. (2015) [46] | 33 | 60.2 (7.8) | 11.7 (4.6) | DBS | NA | 1399.1 (726.1) |
| Li et al. (2017) [42] | 53 | 55.5 (9.1) | 9.8 (4.5) | DBS | NA | 953.20 (398.02) |
| Drapier et al. (2016) [38] | 58 | 66.7 (10.8) | 11.6 (5.4) | CSAI | NA | 1154.1 (758.9) |
| Borgemeester and van Laar (2017) [33] | 58 | 70.9 (8.1) | 10.8 (4.8) | CSAI | 1061 (NA) | NA |
| Martinez-Martin et al. (2015) [43] | 53 | 62.5 (9.9) | 15.1 (5.7) | LCIG vs CSAI | NA | NA |
| Dafsari et al. (2019) [35] | 48 | 63.6 (8.9) | 13.3 (4.8) | DBS vs LCIG vs CSAI | NA | 1300.0 (564.4) |
| Weaver et al. (2009) [13] | 82 | 62.3 (8.9) | 11.7 (5.5) | DBS vs BMT | NA | 1285.2 (534.2) |
| Deuschl et al. (2006) [37] | 64 | 60.7 (7.6) | 13.4 (5.7) | DBS vs BMT | NA | 1175.5 (489.8) |
| Katzenschlager et al. (2018) [12] | 62 | 63.3 (8.8) | 11.2 (5.0) | CSAI vs BMT | 954.7 (490.9) | 1479.1 (638.8) |
| Olanow et al. (2014) [11] | 64 | 60.7 (7.6) | 13.4 (5.7) | LCIG vs BMT | NA | NA |
BMT best medical treatment, CSAI continuous subcutaneous apomorphine infusion, DBS deep brain stimulation, LCIG levodopa/carbidopa intestinal gel, NA not available, SD standard deviation